Company statistics can provide a different perspective on the development of viral vector and plasmid DNA manufacturing. Instead of focusing only on overall industry growth, company-level information helps explain how manufacturers are positioning themselves around gene therapy, cell therapy, plasmid DNA production, and advanced bioprocessing.
The global viral vector and plasmid DNA manufacturing industry was valued at approximately USD 7.26 billion in 2025 and is projected to reach USD 29.82 billion by 2035, expanding at a CAGR of 15.17%. North America represented the largest regional share, accounting for 49% of global revenue in 2025.
These figures provide important context for understanding why companies are increasing their manufacturing capabilities.
U.S. Company Statistics
The U.S. is one of the most important production and development centers for viral vectors and plasmid DNA. According to Precedence Research, the U.S. segment was valued at USD 2.84 billion in 2025 and is expected to reach USD 11.69 billion by 2035, growing at a CAGR of 15.20%.
The competitive environment includes large organizations such as Thermo Fisher Scientific, Lonza, Catalent, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, Aldevron, and Oxford Biomedica, alongside specialized companies such as Andelyn Biosciences and other manufacturing providers.
These companies serve different parts of the manufacturing ecosystem. Some have extensive contract manufacturing operations, while others focus more heavily on specialized plasmid DNA, viral vector, analytical, or cell and gene therapy capabilities.
Download Sample https://www.precedenceresearch.com/sample/1012
What the Numbers Say About Vector Production
Company activity is closely connected to the types of vectors being used in advanced therapies. In U.S. data for 2025, adenovirus represented a significant portion of activity, while lentivirus was identified as a rapidly expanding vector type. In another U.S. dataset from Precedence Research, AAV accounted for 30% of revenue, followed by lentivirus at 20%, adenovirus at 16%, plasmids at 14%, and retrovirus at 11%.
These statistics highlight why manufacturers are building expertise across multiple vector platforms rather than relying on a single technology.
Application data provides another useful perspective. Gene therapy accounted for 45% of U.S. revenue in the 2025 dataset, while cell therapy represented 25%. This reflects the importance of vector manufacturing to the development and commercialization of advanced therapies.
Why Company Statistics Matter
Company statistics become particularly useful when evaluating competitive positioning. Revenue growth alone does not necessarily indicate manufacturing strength. Facility expansion, GMP production capabilities, technology development, partnerships, service breadth, and geographic presence can all influence a company’s position.
For example, established manufacturers are investing in advanced bioprocessing infrastructure and expanding production capabilities as demand from cell and gene therapy developers increases. Precedence Research identifies Thermo Fisher Scientific, Cytiva, Sartorius, and FUJIFILM Diosynth Biotechnologies among companies developing or expanding advanced bioprocessing capacity.
Buy This Report https://www.precedenceresearch.com/checkout/1012
You can place an order or ask any questions, please feel free to contact us at [email protected]
Quick Contact:
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04 and +65 31065601
Visit Our Website: https://www.precedenceresearch.com